NCT02839954View on ClinicalTrials.gov

CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

July 31, 2017

Study Completion Date

July 31, 2018

Conditions
Hepatocellular CarcinomaNon-small Cell Lung CancerPancreatic CarcinomaTriple-Negative Invasive Breast CarcinomaMalignant Glioma of BrainColorectal CarcinomaGastric Carcinoma
Interventions
BIOLOGICAL

anti-MUC1 CAR-pNK cells

Trial Locations (1)

215123

RECRUITING

PersonGen BioTherapeutics (Suzhou) Co., Ltd., Suzhou

Sponsors
All Listed Sponsors
collaborator

The First People's Hospital of Hefei

OTHER

collaborator

Hefei Binhu Hospital

OTHER

lead

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

INDUSTRY